USA flag logo/image

An Official Website of the United States Government

Placental Pathology: Digital Assessment and Validation

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93904
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
HD062307
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PLACENTAL ANALYTICS, LLC
93 COLONIAL AVE LARCHMONT, NY 10538-
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Placental Pathology: Digital Assessment and Validation
Agency: HHS
Contract: 1R43HD062307-01
Award Amount: $125,815.00
 

Abstract:

DESCRIPTION (provided by applicant): Intraamniotic infection is a major risk factor for preterm birth (the greatest single agent of perinatal morbidity and mortality) as well as a contributor to the development of cerebral palsy and other significant child hood diseases. As such, its diagnosis needs to be both reliable (reproducible in the same patient, and across patients and institutions) and valid (consistently predictive of important clinical features of infection, including severity, duration and risk o f sequelae such as neonatal sepsis). Unfortunately, current diagnostic pathology gold standards are neither reliable nor have they been validated against measures other than group consensus , a poor substitute for biologically valid endpoints such as am niotic fluid or cord blood proteomics. Only a handful of US pathologists possess expertise in this diagnosis, with most of these physicians located in academic medical centers, limiting both the absolute numbers of infants who can be provided services as w ell as where such care can be provided. The vast majority of US maternity hospitals therefore effectively lack access to the expert personnel needed to provide such care, resulting in a system in which only a small proportion of newborns can be accurately and reliably assessed for exposure to intraamniotic infections. In this Phase 1 proposal, we will, first, make our algorithms robust to the variability in hematoxylin and eosin staining that would be expected in slides prepared from diverse hospital labora tories. Next, in order to validate these measures, we will take advantage of 2 large data sets in which placentas have already been collected, sampled, sectioned and stained, and slides have been scored (using current standard methods) and digitized, and a team of expert pathologists who have been involved with the data sets and are committed to the project. Using these resources, we will determine the reliability of our product, image analysis software that is a toolbox of algorithm-based image segmentatio n tools that can replace the current best practice (semi-quantitation of neutrophil infiltrates) in routine hematoxylin and eosin (HandE) stained slides. Validation against both expert pathologists and biologically germane endpoints (amniotic fluid or co rd blood proteomics related to infection/inflammation associated molecules) will prepare this diagnostic tool for market introduction to provide state of the art diagnostic care for infants beyond the reach of the small cadre of expert placental patholog ists. In effect, this tool will open the potential for reliable, reproducible and valid diagnoses to be performed at any hospital in the world that can produce a hematoxylin and eosin stained slide. PUBLIC HEALTH RELEVANCE: The fetal inflammatory response, defined as elevated levels of inflammatory cytokines in cord blood and by vasculitis in the umbilical and chorionic vessels of the placenta, predicts recurrence risk for preterm birth (optimizing next pregnancy outcomes), and risks of intraventricular hem orrhage, cerebral white matter damage, cerebral palsy, childhood asthma and lung damage more generally. The current histologic tools used to measure inflammation are limited to a semiquantative estimation of neutrophil number with limited reproducibility e ven among experts . Placental Analytics has developed a set of image processing algorithms for digitized histology slides that promises reliable quantification of the current gold standard for histologic assessment of intraamniotic infection (i.e., neut rophil number), as well as quantification of neutrophil karyorrhexis that may correlate with age/duration of infection more precisely than any current histologic method.

Principal Investigator:

Carolyn M. Salafia
9148343764
CAROLYN.SALAFIA@GMAIL.COM

Business Contact:

Margaret C. Salafia
office@placentalanalytics.com
Small Business Information at Submission:

PLACENTAL ANALYTICS, LLC
PLACENTAL ANALYTICS, LLC 93 COLONIAL AVE LARCHMONT, NY 10538

EIN/Tax ID: 135231173
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No